Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer

Retrieved on: 2024-04-05 23:39:49

Tags for this article:

Click the tags to see associated articles and topics

Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer. View article details on hiswai:

Excerpt

The European Commission (EC) has granted conditional marketing authorization to Roche Holdings AG's (OTC: RHHBY) Gavreto (pralsetinib) for ...

Article found on: www.aol.com